Latest Research And Development News

Page 11 of 115
First Graphene reported unaudited first-quarter income of about A$201,000, up 21% year on year, as PureGRAPH moved into new cement, mining, composites and footwear applications. The commercial pipeline expanded, but A$915,000 of operating cash outflow left the company with A$1.831 million and an estimated two quarters of funding at the reported burn rate.
Victor Sage
Victor Sage
20 Oct 2026
Percheron Therapeutics has secured a funded path towards a Vanderbilt Health-led HMBD-002 trial in high-risk AML and MDS, while ending September with $4.875 million in cash. The biotechnology company also installed a new chief executive and began a preclinical combination study with Invion.
Ada Torres
Ada Torres
20 Oct 2026
PWR Holdings has lifted its FY27 Aerospace and Defence revenue growth outlook to around 50% after delivering record FY26 revenue of $170.7 million. A new US$4.6 million pre-contract order and a planned Polish manufacturing site are adding momentum, although the larger defence opportunity remains subject to customer and program decisions.
Victor Sage
Victor Sage
20 Oct 2026
Microba has secured a $2.025 million placement while cutting costs further, launching GI Navigator and advancing its proposed merger with Genetic Signatures. The funding comes as the company reports strong Australian testing growth but only about one quarter of cash cover before the raise.
Victor Sage
Victor Sage
20 Oct 2026
Actinogen Medical says its pivotal XanaMIA Alzheimer’s trial remains on course for topline results in November after the final patient visit was completed. The company also reported $15.9 million in cash, a further $5.3 million from option funding and a projected runway into late 2027 or 2028, assuming future trials are substantially partner-funded.
Ada Torres
Ada Torres
19 Oct 2026
Acrux has received clearer FDA guidance for Phase III trials of its female testosterone spray, including potential three-year data exclusivity if the product reaches submission. The company also reported positive September-quarter operating cash flow, but that result was largely driven by a $1.977 million R&D tax rebate and Acrux says it is still pursuing funding for the clinical programme.
Victor Sage
Victor Sage
19 Oct 2026
IODM has posted its strongest-ever September revenue as new university contributions accelerate across the UK and Europe, while its cash position leaves little room for execution missteps. The company ended the quarter with A$747,000 in cash and an estimated 1.2 quarters of funding.
Sophie Babbage
Sophie Babbage
19 Oct 2026
Nyrada has moved its PROTECT-MI heart-attack trial into active recruitment, with four hospitals open and three patients dosed. The biotech also reported supportive US FDA feedback, encouraging preclinical oncology data and AU$13.72 million in cash after a AU$12 million placement.
Ada Torres
Ada Torres
19 Oct 2026
Hazer Group has expanded its commercial pipeline through a paid Japanese utility study assessing hydrogen facilities of up to 300,000 tonnes per year, while its KBR alliance advances a standardised commercial-scale design. The company ended September with A$8.3 million in cash and reported A$12.9 million in pro-forma funding, but remains pre-revenue in the quarter.
Victor Sage
Victor Sage
19 Oct 2026
Noxopharm has completed its first-in-human safety trial for SOF-SKN and advanced the wider Sofra platform, but its annual report flags a material uncertainty over funding. The biotech ended June with A$293,573 in cash, net liabilities of A$3.65 million and a need for additional capital.
Ada Torres
Ada Torres
16 Oct 2026
Weebit Nano has begun silicon validation with a second customer whose chip is running software from integrated ReRAM, marking another step towards potential production in 2027. The company also added two AI customers, advanced qualification work and ended the quarter with A$164.2 million in cash.
Victor Sage
Victor Sage
16 Oct 2026
Titomic will restructure its Australian and US operations and reduce consultant spending, targeting A$3.0 million in annualised operating cost savings. The company expects to complete the changes by October’s end while repositioning Australia as its global research and development centre.
Victor Sage
Victor Sage
15 Oct 2026

Browse the archive

Full archive